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substantial separation of behavioral effects may be accomplished by apparently non-
selective modulators. We report on SH-I-048A, a newly synthesized chiral positive
modulator of GABAA receptors characterized by exceptional subnanomolar afﬁnity, high
efﬁcacy and non-selectivity. Its inﬂuence on behavior was assessed in Wistar rats and
contrasted to that obtained with 2 mg/kg diazepam. SH-I-048A reached micromolar
concentrations in brain tissue, while the unbound fraction in brain homogenate was
around 1.5%. The approximated electrophysiological responses, which estimated free
concentrations of SH-I-048A or diazepam are able to elicit, suggested a similarity between
the 10 mg/kg dose of the novel ligand and 2 mg/kg diazepam; however, SH-I-048A was
relatively more active at α1- and α5-containing GABAA receptors. Behaviorally, SH-I-048A
induced sedative, muscle relaxant and ataxic effects, reversed mechanical hyperalgesia
24 h after injury, while it was devoid of clear anxiolytic actions and did not affect water-
maze performance. While lack of clear anxiolytic actions may be connected with anr B.V. All rights reserved.
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b r a i n r e s e a r c h 1 5 5 4 ( 2 0 1 4 ) 3 6 – 4 8 37enhanced potentiation at α1-containing GABAA receptors, the observed behavior in the
rotarod, water maze and peripheral nerve injury tests was possibly affected by its
prominent action at receptors containing the α5 subunit. The current results encourage
further innovative approaches aimed at linking in vitro and in vivo data in order to help
deﬁne ﬁne-tuning mechanisms at four sensitive receptor populations that underlie subtle
differences in behavioral proﬁles of benzodiazepine site ligands.
& 2014 Elsevier B.V. All rights reserved.Table 1 – Binding afﬁnity (Ki, nM) of SH-I-048A and
diazepam at human recombinant GABAA receptors con-
taining β3, γ2 and named α subunit, stably expressed in
mouse ﬁbroblast L(tk ) cells; ND – not detected. [3H]
ﬂunitrazepam was used as the radiolabelled ligand in the
competition binding assay. Data for diazepam were
published in Savi� et al. (2010).
Ligand α1 α2 α3 α4 α5 α6
SH-I-
048A
0.77 0.17 0.38 ND 0.11 ND
Diazepam 14.0 7.8 13.9 ND 13.4 ND1. Introduction
Ionotropic receptors for the inhibitory neurotransmitter
γ-aminobutyric acid (GABA) are the most widely distributed
receptors in the central nervous system (Watanabe et al., 2002)
and at the same time successfully exploited drug targets
(Sieghart, 2006). Among drugs acting through GABAA receptors,
benzodiazepines (BZs) have been established as especially
versatile GABA-modulatory drugs. However, a plethora of
regulatory roles of GABA itself is reﬂected in a wide range of
pharmacological actions of BZs and an increased burden of side
effects. The recognition that the molecular substrate of BZ
action comprises four populations of GABAA receptors which
contain the α1, α2, α3 or α5 subunit, in addition to the γ2 subunit,
has given an impetus for synthesis and development of newer
ligands. It was hypothesized that four populations of BZ-
sensitive GABAA receptors mediate distinct sets of behavioral
responses, enabling separation of desirable effects mediated by
one, from undesirable effects supposedly mediated by the other
subtype of receptors (Olsen and Sieghart, 2008; Rudolph and
Möhler, 2006).
A number of subtype selective ligands acting at the BZ site
have been reported in recent years, with the ﬁnal aim of
obtaining the optimal balance between efﬁcacy and safety
and possibly broadening the current spectrum of indications
(Rudolph and Knoﬂach, 2011). This concept pursued the results
of genetic studies, which have attributed the sedative and
ataxic properties of BZs to the predominantly expressed α1
subunit-containing GABAA receptors, the anxiolytic, muscle
relaxant and antihyperalgesic actions to the α2/α3 subtype-
containing receptors, and anticonvulsant activity to all, the
α1/α2/α3 GABAA receptors (reviewed in Rudolph and Möhler,
2006). Despite promising preclinical data, no clear clinical
breakthroughs have been made to date (Atack et al., 2011)
and, indeed, the whole concept has been questioned to a
certain degree (Skolnick, 2012). Especially puzzling were the
results suggesting that substantial improvement in the beha-
vioral proﬁle may be accomplished by non-selective ligands
active at all four populations of BZ-sensitive GABAA receptors
(Auta et al., 2010; Rabe et al., 2007), or even predominantly
active at GABAA receptors containing the α1 subunit (Lippa
et al., 2005; Popik et al., 2006). Such ﬁndings were clearly at odds
with results from genetic studies showing that sedation and
motor impairments exerted by BZs depend to a high degree on
positive modulation of α1 GABAA receptors (Atack, 2010). The
predominantly, though not exclusively hippocampus-based α5
GABAA receptors are thought to contribute to amnesic effects of
BZs (Rudolph and Möhler, 2006), but their biological role is also
the subject of debate, because a number of results suggest thatactivation of these receptors may facilitate memory processing
(Koh et al., 2013; McEown and Treit, 2013), as well as reduce
psychotic symptoms (Gill et al., 2011).
To tackle the problem in a stepwise way, we hereby report on
a newly synthesized chiral positive modulator of GABAA recep-
tors characterized by high afﬁnity, high efﬁcacy and non-
selectivity, which was examined for its brain exposure and
pharmacodynamic proﬁle in rats. In order to estimate pharma-
cologically active drug concentrations, we calculated the
unbound concentrations in brain (Hammarlund-Udenaes, 2010;
Read and Braggio, 2010). In vitro and in vivo properties, as well as
brain exposure of SH-I-048A were directly compared with data
generated, under identical experimental conditions, for the
standard non-selective BZ site positive modulator, diazepam.
The chosen battery of behavioral tests included those assessing
motor status of the animal (spontaneous locomotor activity,
rotarod, and grip strength), its anxiety level (open ﬁeld and
elevated plus maze), learning and memory capability (Morris
water maze) and pain susceptibility (model of peripheral nerve
injury). We hypothesized that a ligand with an in vitro/ex vivo
proﬁle demonstrating superiority or, at least, non-inferiority to
diazepam, in terms of availability at the receptor site and its
subsequent modulation, should exert a set of in vivo actions
comparable to those repeatedly reported for diazepam (Rudolph
and Knoﬂach, 2011). Potential failures to support the hypothesis
would prove that assigning various behavioral effects to any of
speciﬁc GABAA receptor populations demands further reﬁning
and obtaining more comprehensive experimental data than
usually presented (cf. Skolnick, 2012).2. Results
2.1. In vitro afﬁnity
The in vitro binding data for SH-I-048A, in parallel with those for
diazepam, are presented in Table 1. The novel ligand showed
b r a i n r e s e a r c h 1 5 5 4 ( 2 0 1 4 ) 3 6 – 4 838very high (subnanomolar) afﬁnity for BZ-sensitive recombinant
human GABAA receptors, considerably higher than that of
diazepam. Furthermore, no major selectivity in binding at one
over the other subtype was noticed (quite similar to diazepam).
2.2. Electrophysiological experiments
Electrophysiological behavior of SH-I-048A and the reference
benzodiazepine diazepam in a wide range of concentrations
(1 nM–10 μM) is presented in Fig. 1. The novel ligand exerted
higher positive modulation than diazepam at all four rat
recombinant GABAA receptor subtypes. In addition, it seemed
to interact with a second binding site at concentrations41 μM,
as indicated by the mathematical ﬁt of the data points by a
biphasic dose-response simulation using GraphPad Prism. EC50
values used by this program for ﬁtting the SH-I-048A data wereFig. 1 – Effects of SH-I-048A and diazepam at different GABAA re
048A at α1β3γ2, α2β3γ2, α3β3γ2 and α5β3γ2 receptors (n¼3–5). Below
presence of increasing SH-I-048A concentrations at α1β3γ2 recept
α2β3γ2, α3β3γ2 and α5β3γ2 receptors (n¼5–9). Below: Individual cur
increasing diazepam concentrations at α1β3γ2 receptors. Data are
Table 2 – Total and estimated free concentrations of SH-I-048A
after 20 and 60 min.
Dose (mg/kg) 0.5 2
Time (min) 20 20
Plasma (nmol/L) Total 187.59726.66 818.82757.06
Free 8.43 36.79
Brain (nmol/kg) Total 231.12752.27 750.597307.14
Free 3.26 10.6014 nM and 2560 nM; 14 nM and 1410 nM; 20 nM and 2830 nM;
or 12 nM and 2670 nM, for α1β3γ2, α2β3γ2, α3β3γ2, or α5β3γ2
containing receptors, respectively. Although an interesting
ﬁnding, we did not further investigate this low potency
interaction of SH-I-048A because the high free concentrations
of the ligand required to generate relevant effects via this
second site (probably well above 100 nM) were not reached
under the conditions used (see Section 2.3.1) and thus could
not have contributed to the results of the present study.
2.3. Estimation of free plasma and brain concentrations
2.3.1. Quantiﬁcation in rat plasma and brain tissue
The concentrations of SH-I-048A in rat plasma (nmol/L) and
brain tissue (nmol/kg), both total and free (estimated), are
shown in Table 2. Free concentrations of SH-I-048A wereceptor subtypes. (a) Concentration–response curves of SH-I-
: Individual current traces of GABA EC3 in the absence or
ors. (b) Concentration–response curves of diazepam at α1β3γ2,
rent traces of GABA EC3 in the absence or presence of
mean values7SEM.
(dosed at 0.5, 2 and 10 mg/kg) in plasma and brain samples
10
60 20 60
617.877149.35 1591.4175.15 1396.197492.70
27.76 71.50 62.73
739.377182.94 2096.337858.32 1035.237421.19
10.45 29.62 14.63
b r a i n r e s e a r c h 1 5 5 4 ( 2 0 1 4 ) 3 6 – 4 8 39calculated by multiplying the measured total plasma and brain
concentrations with the appropriate estimated free fractions.
2.3.2. Plasma protein and brain tissue binding studies
Free fractions of SH-I-048A in rat plasma and brain tissue
determined by rapid equilibrium dialysis were 4.49% and 1.41%,
respectively.
2.3.3. Assessment of in vivo efﬁcacy
The exact in vitro efﬁcacy values for SH-I-048A and diazepam at
each of four recombinant GABAA receptor subtypes, used for
the mathematical ﬁt presented in Fig. 2, were applied to
calculate linear equations between two concentrations adjacent
to the estimated in vivo free brain concentrations, which are
presented in Table 2 for SH-I-048A, while the estimated free
concentration of 2 mg/kg diazepam equals 58.46 nmol/kg (Savić
et al., unpublished data). For example, in vitro efﬁcacies of SH-I-
048A at α1β3γ2 receptors are 124% and 256%, for concentrations
of 1 nM and 10 nM, respectively, giving rise to potentiation of
157% when in vivo free concentration of 3.26 nM was applied to
the corresponding linear equation; the values calculated by this
approach are presented in Fig. 7.
2.4. Behavioral experiments
2.4.1. Spontaneous locomotor activity
The inﬂuence of SH-I-048A (dosed at 2, 5 and 10 mg/kg) on the
total distance traveled during 30 min of monitoring did not
reach statistical signiﬁcance, as assessed by a one-way
ANOVA (F(3,28)¼2.76, p¼0.061) (the inset of Fig. 2a). WhenFig. 2 – The effects of SH-I-048A on the (a) total distance traveled
arm entries of elevated plus maze, (c) total distance traveled in o
compared to the solvent (SOL) group. Data represent mean7SEM
was 8, while in (b) and (c) was 7.the analysis of distance traveled was developed into 5 min
bins (Fig. 2a), it turned out that rats treated with SH-I-048A,
dosed at 5 and 10 mg/kg, traveled shorter distances than the
solvent-treated animals during the second time interval
(5–10 min) (p¼0.017 and p¼0.008, respectively).2.4.2. Elevated plus maze
A one-way ANOVA showed no signiﬁcant effect of treatment on
the number of closed arm entries (F(3,24)¼2.64, p¼0.072; Fig. 2b).
Regarding the anxiety-related parameters, the same statistical
analysis revealed that the effect of treatment on the percentage
of the time spent on open arms was not signiﬁcant, but again a
statistical trend was noted (F(3,24)¼2.37, p¼0.095; Fig. 3a).
However, ANCOVA revealed that the trend of SH-I-048A to
increase this parameter, related to anxiolytic-like activity, dis-
appeared when the concomitant inﬂuence on closed arm entries
was taken into account (F(3,23)¼2.22, p¼0.113). The doses of 0.5
and 2mg/kg tested in a preliminary study were devoid of any
inﬂuences on the EPM parameters (data not shown).2.4.3. Open ﬁeld test
A one-way ANOVA revealed a signiﬁcant effect of treatment
on the total distance traveled in the open ﬁeld arena (F(4,30)¼
11.48, po0.001; Fig. 2c). Dunnett's post hoc test showed that
only SH-I-048A (10 mg/kg) signiﬁcantly decreased the total
distance traveled, when compared to the solvent group
(po0.001). Anxiety-related parameter (the percent of time
spent in the central zone) was not signiﬁcantly affected, as
assessed by a one-way ANOVA (F(4,3¼0.60, p¼0.669; Fig. 3b).in spontaneous locomotor activity test, (b) number of closed
pen ﬁeld test, and (d) grip strength. nnpo0.01 and nnnpo0.001,
. Number of animals per each treatment group in (a) and (d)
Fig. 4 – The effects of SH-I-048A (10 and 25 mg/kg) in the absence (β-CCt 0) and the presence of 30 mg/kg β-CCt (β-CCt 30) on
ataxia in the rotarod test: (a) 30 min, (b) 60 min, and (c) 90 min after treatment.þpo0.05, þþpo0.01 and þþþpo0.001 compared
to SH-I-048A 10þβ-CCt 0 group; #po0.05 and ##po0.01 compared to SH-I-048A 25þβ-CCt 0 group. Data represent mean7SEM.
Number of animals per treatment varied from 6 to 8.
Fig. 3 – The effects of SH-I-048A (2, 5 and 10 mg/kg) on the (a) percentage of time spent on open arms and (b) percentage
of spent in the central zone of the open ﬁeld arena. Data represent mean7SEM.
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A one-way ANOVA revealed a signiﬁcant effect of treatment
on grip strength (F(4,35)¼7.48, po0.001; Fig. 2d). Post hoc
Dunnett's test showed that rats treated with SH-I-048A (2, 5
and 10 mg/kg) experienced signiﬁcant muscle relaxation
compared to the control (solvent) group (p¼0.002, po0.001
and p¼0.002, respectively).
2.4.5. Rotarod test
When three separate two-way ANOVAs (SH-I-048A and β-CCt, as
factors) were applied at each time point, the only signiﬁcant
factor was β-CCt (after 0.5 h: F(1,24)¼9.91, p¼0.004; after 1 h: F
(1,24)¼30.02, po0.001, and after 1.5 h: F(1,24)¼26.38, po0.001).
Post hoc Tukey test showed that the addition of β-CCt to both 10
and 25mg/kg SH-I-048A increased latency to fall from the
revolving rod at 0.5 h (p¼0.031 and p¼0.040, respectively;
Fig. 4a), after 1 h (po0.001 and p¼0.008, respectively; Fig. 4b),
and ﬁnally after 1.5 h (p¼0.001 and p¼0.002, respectively; Fig. 4c).
2.4.6. Morris water maze
Regarding the dose response study of SH-I-048A in the water
maze, a two-way ANOVA with repeated measures revealed that
only factor Days were signiﬁcant, for both the latency to ﬁnd
the platform (treatment: F(3,24)¼0.88, p¼0.467; day: F(4,96)¼
46.77, po0.001; and treatmentday: F(12,96)¼0.59, p¼0.843;
Fig. 5a) and the path efﬁciency (treatment: F(3,24)¼0.89,p¼0.463; day: F(4,96)¼28.40, po0.001; and treatmentday: F
(12,96)¼0.61, p¼0.825; Fig. 5b). A one-way ANOVA applied on
the data from the probe test revealed no signiﬁcant effect of
factor treatment on both parameters measured: the latency to
the ﬁrst entry to the target zone (F(3,24)¼0.28, p¼0.841) and the
path efﬁciency to the ﬁrst entry to the target zone (F(3,24)¼0.73,
p¼0.542).
2.4.7. Peripheral nerve injury model
A two-way ANOVA with repeated measures showed that both
factors were signiﬁcant (treatment: F(3,20)¼7.83, p¼0.001;
time: F(2,40)¼124.50, po0.001; Fig. 6). Since a signiﬁcant
interaction between these two factors was also determined
(F(6,40)¼3.07, p¼0.015), we decided to use one-way ANOVAs
(for each of three levels of factor Time) to analyze simple
main effects. A one-way ANOVA followed by Tukey’s post hoc
analysis showed no signiﬁcant differences between all groups
at the baseline time (0 h). After 24 h, the same statistical
procedure showed that rats treated with three doses of SH-I-
048A (10 mg/kg) exhibited signiﬁcantly higher paw withdra-
wal threshold compared to the solvent group (p¼0.015), those
treated with only one dose (po0.001), as well as to rats
treated with two doses of SH-I-048A (p¼0.019). A one-way
ANOVA applied on the data measured 48 h after surgery
revealed no signiﬁcant effect of factor Treatment on paw
withdrawal threshold (F(3,2)¼1.93, p¼0.157). Regarding the
Fig. 6 – The effects of three treatment combinations
comprising solvent (SOL) and/or 10 mg/kg SH-I-048A (SH),
administered immediately after surgery (0 h), 12 h later
(þ 12 h) and after 23 h (þ23 h), on the ratios between the
right (injured) hind paw and left hind paw responses,
obtained by dividing the two values and then multiplying
the result by 100, in the peripheral nerve injury model,
measured at the baseline (0 h), 24 and 48 h after injury.
npo0.05 compared to 3SOL group, ###po0.001 compared to
1SH-I-048Aþ2SOL group, and þpo0.05 compared to
2SH-I-048Aþ1SOL group. Data represent meanþSEM.
Number of animals per each treatment group was 6.
Fig. 5 – The effects of SH-I-048A (0.5, 2 and 10 mg/kg) on the
water maze parameters: (a) the latency to reach the platform
and (b) the path efﬁciency. Data represent mean7SEM.
Number of animals per each treatment was 7.
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ANOVA with repeated measures showed that both factors, as
well as their interaction, were without signiﬁcant effect
(treatment: F(3,20)¼1.99, p¼0.148; time: F(2,40)¼1.073,
p¼0.352; and treatment time F(6,40)¼1.98, p¼0.091).
2.4.8. Studies with diazepam as positive control
Table 3 demonstrates the results of behavioral studies with
2 mg/kg diazepam in comparison to the appropriate control
group and, in parallel, the above-presented data for 10mg/kg
SH-I-048A and its control. Although the effects of ligands were
generally similar, the observed behavioral inactivity of SH-I-
048A in MWM was distinctly different from the incapacitating
effect of diazepam during ﬁve days of acquisition. This ﬁnding
was not accompanied by signiﬁcant differences in the overall
latencies during ﬁve acquisition days for solvent-treated
animals from experiments with diazepam and SH-I-048A,
respectively (F(1,69)¼ 3.169, p¼0.100). The only signiﬁcant
difference between controls in two experiments was for the
percent time spent in the central zone in OF (data not shown);
this discrepancy was probably related to subtle differences in
illumination used and also to the well-known variability of
results obtained in this test (Prut and Belzung, 2003).3. Discussion
In recent years, several research groups, including ours, have
reported on a number of ligands for the BZ site of GABAA
receptors which possessed in vitro selectivity for one or two
populations of BZ-sensitive receptors, and as a rule low
activity at GABAA receptors containing the α1 subunit (e.g.
Atack et al., 2011; Griebel et al., 2001; Mirza et al., 2008; Savić
et al., 2010). Their in vivo proﬁles were mainly in line with the
results of genetic studies, which, as a ﬁnding of special
clinical relevance, associated motor impairing effects with
activation of receptors containing the α1 subunit (reviewed in
Rudolph and Möhler, 2006). At the same time, there have
been some promising developments also of ligands report-
edly non-selective in afﬁnity and efﬁcacy at GABAA receptors
(Auta et al., 2010; Rabe et al., 2007), or even predominantly
active at receptors containing the α1 subunit (Lippa et al.,
2005; Popik et al., 2006), but still showing a low potential for
motor deﬁcits in animals. In order to shed some additional
light on these apparently contradictory results, we discovered
and pharmacologically characterized SH-I-048A, a non-
selective ligand that exhibited an exceptional, subnanomolar
capacity to bind to all four BZ-sensitive GABAA receptors and
also strongly potentiated the inhibitory effect of GABA,
mediated through these receptors. Its overall ability to
change the rat's behavior was similar, but far from identical,
to that characterizing diazepam at the most commonly used
2 mg/kg dose.
Table 3 – Numeric values for diazepam (DZP, 2 mg/kg), SH-I-048A (10 mg/kg) and their appropriate solvent controls (SOL)
in behavioral experiments. Each value is the mean7SEM of 6-8 rats. Data for SH-I-048A and its solvent control are also
graphically presented in Figs. 2–5.
Test/parameter SOL DZP (2 mg/kg) p values
(SOL vs.
DZP)
SOL SH-I-048A
(10 mg/kg)
p values
(SOL vs.
SH-I-048A)
SLA total distance (m) 16.671.51 7.1771.13nnn po0.001 14.0171.47 6.4272.26n p¼0.014
EPM number of closed
arm entries % time on
open arms
5.3670.89 4.0970.77 p¼0.306 6.4370.30 4.0071.23 p¼0.080
40.0079.17 76.6776.67nn p¼0.009 35.7177.68 67.43712.34n p¼0.050
OF total distance (m) %
time in central zone
53.9174.68 24.5075.34nnn p¼0.001 53.3673.56 15.3975.35nnn po0.001
2.1170.42 3.0971.15 p¼0.437 7.0471.06 30.01715.49 p¼0.165
GS grip strength (g/kg) 2698.337211.36 1722.507197.65nn p¼0.007 3477.307154.85 2588.837169.52nn p¼0.002
RR time on rotarod (s) 120.0070.00 41.7079.79nnn po0.001 120.0070.00 0.2570.16nnn po0.001
MWM latency (s)
Day 1 73.9279.14 103.45710.64 p¼0.057 101.1075.97 102.1179.11 p¼0.927
Day 2 64.84713.09 92.8276.40 p¼0.079 73.75711.58 88.5279.40 p¼0.342
Day 3 31.5776.37 77.83715.52n p¼0.017 38.6879.21 62.98714.13 p¼0.175
Day 4 37.6678.79 59.0279.78 p¼0.130 26.5675.82 53.39714.74 p¼0.116
Day 5 17.6173.10 56.40710.20nn p¼0.003 35.11710.09 42.65713.99 p¼0.670
n po0.05.
nn po0.01.
nnn po0.001 compared to the respective SOL.
Fig. 7 – Approximated electrophysiological behavior of the estimated free brain concentrations, based on the total brain
concentrations measured 20 min after i.p. administration of SH-I-048A (0.5, 2 and 10 mg/kg) and diazepam (2 mg/kg; DZP 2).
The estimated free concentrations of SH-I-048A are given in Table 2, while the estimated free concentration of 2 mg/kg
diazepam equals 58.46 nmol/kg (Savić et al., unpublished data). The bars indicate the stimulation of the individual αxβ3γ2
GABAA receptors at these concentrations, as extrapolated from data presented in Fig. 1.
b r a i n r e s e a r c h 1 5 5 4 ( 2 0 1 4 ) 3 6 – 4 842The ligand SH-I-048A is structurally closely related to
typical benzodiazepines such as diazepam and ﬂurazepam,
except that it contains a chiral methyl function at C-3 with the
S-conﬁguration. Previously, in another series of ligands, it was
demonstrated that the binding, efﬁcacy and in vivo activity of
ligands which contain a chiral S-CH3 group at C-4 (similar to
the C-3 S-CH3 function in SH-I-048A) is different than the R-
CH3 isomer (Fischer et al., 2010; Savić et al., 2010). Importantly,
the R-enantiomer of SH-I-048A was almost completely inactive
in the same oocyte assay (not shown), consequently stimulat-
ing interest in the study of chiral S-enantiomer described in
this manuscript. Hence this chiral function would be expectedto alter the proﬁle of SH-I-048A vs. diazepam. The question
was to what extent and how.
It is generally accepted that the receptor effects, beside
afﬁnity and efﬁcacy, depend on the available unbound ligand
(Hammarlund-Udenaes, 2010; Read and Braggio, 2010). Here,
we present an innovative approach aimed to compare brain
exposure and electrophysiological data obtained for SH-I-048A
to the results for diazepam, observed in the same experimen-
tal settings. The approximated electrophysiological responses,
which the estimated free concentrations of two ligands are
able to elicit (Fig. 7), suggest that the 2 mg/kg dose of diazepam
corresponds to a ﬁve times higher dose of the novel ligand, at
b r a i n r e s e a r c h 1 5 5 4 ( 2 0 1 4 ) 3 6 – 4 8 43least after intraperitoneal administration in Wistar rats. Such
a relation could not have been predicted solely from knowl-
edge of the in vitro properties. Moreover, any discrepancies in
in vivo proﬁles could be governed by relative differences in the
approximated receptor activity of diazepam and SH-I-048A.
Most remarkably, a substantial difference related to α1- and α5-
containing GABAA receptors, at which SH-I-048A is relatively
more active than diazepam, could be noted in Fig. 7.
SH-I-048A dose-dependently affected parameters of gen-
eral motor activity and dexterity, in a manner similar to
diazepam (Milić et al., 2012; Savić et al., 2009; Siemiatkowski
et al., 2000). Among parameters of locomotor activity, the
statistical signiﬁcance of the sedative effect was reached for
distance traveled during the recording period 5–10 min in
SLA, at doses of 5 and 10 mg/kg, and the total distance
traveled in OF, at the dose of 10 mg/kg. Grip strength,
measuring muscle relaxant effect, was moderately, but sig-
niﬁcantly reduced at doses of 2–10 mg/kg. Having in mind
non-selectivity of SH-I-048A, these two sets of results con-
form with the postulate that sedation is mediated by α1
GABAA receptors, and muscle relaxation by α2 and α3 GABAA
receptors (Rudolph and Knoﬂach, 2011).
While our recent results showed that the administration
of β-CCt fully antagonized the impairment of motor coordi-
nation in rats induced by diazepam (Milić et al., 2012), the
antagonist effect of this α1-selective ligand on the prolonged
rotarod incapacitation induced by SH-I-048A was signiﬁcant,
but still not sufﬁcient enough to enable the rats to regain the
control performance, especially at the 30 min time point,
when they spent less than 40 s on the revolving rod, far
different from the basal value of 120 s. Since our analysis
(Fig. 7) suggested a similarity of the effects of SH-I-048A and
diazepam elicited at α2 and α3 GABAA receptors, the difference
in the behavioral effect has probably been contributed to the
population of α5-containing GABAA receptors, which are more
activated by SH-I-048A than by diazepam.
Diazepam in a range of moderate doses commonly exerted
anxiolytic-like actions in the EPM (Savić et al., 2010) and OF
(Prut and Belzung, 2003), whereas SH-I-048A, applied in a
wide range of doses (0.5–10 mg/kg in EPM and 0.2–10 mg/kg in
OF), did not signiﬁcantly affect the parameters of anxiety-
related behavior in either of these two anxiety tests. More-
over, the observed tendency of SH-I-048A to induce
anxiolytic-like changes at the dose of 10 mg/kg appeared to
be confounded by locomotor inﬂuences, as indicated by the
results of statistical analysis which involved the number of
closed arm entries as a covariate. We hypothesize that the
motor effects mediated by an enhanced potentiation at α1
and/or α5 GABAA receptors, relative do diazepam, probably
hampered the anxiolytic actions of SH-I-048A expected to be
effected by α2 and/or α3 GABAA receptors (Rudolph and
Knoﬂach, 2011). The results from OF and tests of motor
activity suggest that even diazepam at the dose of 2 mg/kg
was prone to elicit suppressing motor effects which may
compromise the assessment of anxiety-like behaviors.
The results obtained in MWM demonstrated a lack of BZ-
characteristic impairment of learning and memory para-
meters during acquisition sessions and probe trial. This
ﬁnding is clearly different from the well-established incapa-
citating actions of diazepam (Arolfo and Brioni, 1991) andgenerally unexpected, especially bearing in mind the notice-
able activity of SH-I-048A at α1 and α5 GABAA receptors, which
were shown to contribute to the water-maze incapacitation
exerted by diazepam (Savić et al., 2009). Noteworthy, the rats
dosed with 10 mg/kg SH-I-048A, apparently heavily sedated
immediately before being placed into the water-maze,
appeared vigilant when confronted with a challenging task.
While seemingly unexplainable in the scope of the results of
genetic studies (Rudolph and Knoﬂach, 2011), the observed
‘behavioral silence’ of SH-I-048A in MWM may be connected
with the recent ﬁnding that potentiation of α5 GABAA recep-
tors increases ﬁring rates of cortical neurons during episodes
of ongoing neuronal activity (up states) (Drexler et al., 2013).
In this vein, the observed higher activity at α5 GABAA
receptors of SH-I-048A compared to diazepam may have
contributed to a kind of compensatory effect on MWM
performance, noted in the current investigation.
The decrease of GABA neurotransmission in the spinal
cord contributes to the enhanced pain sensitivity observed in
pain states, especially those of neuropathic nature (Munro
et al., 2009). At the behavioral level, it was shown that GABAA
receptor positive allosteric modulators, such as diazepam,
attenuate nociceptive transmission in animal models of
neuropathic pain (Knabl et al., 2009; Malan et al., 2002). The
present study has focused on sciatic crush injury (Bester
et al., 2000), which mimics a common and refractory dis-
ability. SH-I-048A, administered in three 10 mg/kg doses, has
reversed mechanical hyperalgesia 24 h after injury, as mea-
sured 1 h after administration of the last dose. Motor inca-
pacitation elicited by the novel ligand, demonstrated in tests
of motor function, cannot be seen as substantially confound-
ing these results, having in mind normal responses of
uninjured hind paws. Although the antihyperalgesic inﬂu-
ence of treatment was statistically not signiﬁcant 48 h after
injury, there was still a certain level of the residual effect in
the group injected thrice with SH-I-048A. In the more com-
mon chronic constriction injury model, which could be
regarded as similar to the crush injury model used in the
present study, it was shown that diazepam was able to
attenuate hind paw hypersensitivity at the highest dose
tested (10 mg/kg) (Munro et al., 2008). On the contrary,
zolpidem, a positive modulator highly effective at α1-, mod-
erately effective at α2/3- and ineffective at α5 GABAA receptors
(Savić et al., 2010), was completely inactive in the same model
(Munro et al., 2008). Genetic and pharmacological studies
have focused on the role of benzodiazepines in central pain
transmission on the population of α2/3 GABAA receptors
(Di Lio et al., 2011; Knabl et al., 2008). However, a number of
studies have pointed to α5-containing receptors as possibly
contributing to GABA-mediated antihyperalgesia (Nickolls
et al., 2011). A substantial potential of antihyperalgesic action
of SH-I-048A dosed thrice at 10 mg/kg may be seen as further
adding to the possible role of α5 GABAA receptors, otherwise
moderately present in the spinal cord (Paul et al., 2012), in
modulation of pain transmission.
In conclusion, this paper presented SH-I-048A, a novel,
chiral, highly potent and efﬁcacious positive allosteric mod-
ulator at the BZ site of recombinant GABAA receptors. Appar-
ently small differences in the simulated in vivo environment,
approximated on the basis of electrophysiological, equilibrium
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a number of differences in behavioral proﬁles of SH-I-048A and
diazepam, which may be connected with relatively higher
activity of SH-I-048A at α1 and/or α5 GABAA receptors. It
appears crucial to establish ﬁrmer links between in vitro and
in vivo data in order to help deﬁne the criteria for declaring
selectivity or non-selectivity of BZ site ligands, and the
presented approximation of activation of GABAA receptor
subtypes may be a valuable approach. The current results
suggest that diazepam, commonly seen as a prototype of non-
selective BZ site ligands, does possess a kind of ‘semi-selec-
tivity’ towards α2 and α3 GABAA receptors, far different from
SH-I-048A, which thus proved to be a useful experimental tool.4. Experimental procedures
4.1. Drugs
The novel chiral compound SH-I-048A ((S)-7-bromo-5-(2-
ﬂuorophenyl)-3-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one)
and β-CCt (t-butyl-β-carboline-3-carboxylate), the preferential
α1-containing GABAA receptor selective antagonist, were
synthesized at the Department of Chemistry and Biochem-
istry, University of Wisconsin – Milwaukee, while diazepam
was obtained from Galenika (Belgrade, Serbia).
4.2. Competition binding assays
Competition binding assays were performed in a total volume
of 0.5 mL at 4 1C for 1 h using [3H]ﬂunitrazepam as the
radiolabelled ligand. A total of 6 μg of cloned human GABAA
receptor DNA containing the desired α subtype along with β2
and γ2 subunits were used for transfecting HEK 293T cell lines
using Fugene 6 (Roche Diagnostic) transfecting reagent. Cells
were harvested 48 h after transfection, washed with Tris–HCl
buffer (pH 7.0) and Tris–acetate buffer (pH 7.4) and the
resulting pellets were stored at 80 1C until assayed. On the
day of the assay, pellets containing 20–50 μg of GABAA
receptor protein were resuspended in 50 mM Tris–acetate
pH 7.4 at 4 1C and incubated with the radiolabel as previously
described (Choudhary et al., 1992). Nonspeciﬁc binding was
deﬁned as radioactivity bound in the presence of 100 μM
diazepam and represented less than 20% of total binding.
Membranes were harvested with a Brandel cell harvester
followed by three ice-cold washes onto polyethyleneimine-
pretreated (0.3%) Whatman GF/C ﬁlters. Filters were dried
overnight and then soaked in Ecoscint A liquid scintillation
cocktail (National Diagnostics; Atlanta, GA). Bound radio-
activity was quantiﬁed by liquid scintillation counting. Mem-
brane protein concentrations were determined using an
assay kit from Bio-Rad (Hercules, CA) with bovine serum
albumin as the standard.
4.3. Electrophysiological experiments
cDNAs of rat GABAA receptor subunits were used for generating
the respective mRNA's that were then injected into Xenopus
laevis oocytes (Nasco, WI) as described previously (Ramerstorfer
et al., 2010). For electrophysiological recordings, oocytes wereplaced on a nylon-grid in a bath of Xenopus Ringer solution (XR,
containing 90mM NaCl, 5 mM HEPES-NaOH (pH 7.4), 1 mM
MgCl2, 1 mM KCl and 1mM CaCl2). The oocytes were constantly
washed by a ﬂow of 6 mL/min XR which could be switched to
XR containing GABA and/or drugs. Drugs were diluted into XR
from DMSO-solutions resulting in a ﬁnal concentration of 0.1%
DMSO perfusing the oocytes. Drugs were preapplied for 30 s
before the addition of GABA, which was coapplied with the
drugs until a peak response was observed. Between two
applications, oocytes were washed in XR for up to 15min to
ensure full recovery from desensitization. To test for modula-
tion of GABA-induced currents by drugs, a concentration of
GABA was used that was titrated to trigger 3% of the respective
maximum GABA-elicited current of the individual oocyte (EC3).
At this low GABA concentration, within-day and between-day
currents are reproducible and effects of drugs (% of modulation)
are much higher than that at higher GABA concentrations,
again contributing to the accuracy of the results. In addition,
such low GABA concentrations correspond to those acting at
extrasynaptic receptors that represent the majority of GABAA
receptors in the brain (Kasugai et al., 2010). In contrast, GABA
concentrations acting at synaptic GABAA receptors in many
cases fully activate these receptors. At such GABA concentra-
tions benzodiazepines cannot enhance GABA currents any-
more, but they prolong current decay. This effect, however, is
antagonized by a simultaneously occurring rapid receptor
desensitization making measurements unreliable. The GABA
EC3 concentration was applied to the cell together with various
concentrations of drugs. For current measurements the oocytes
were impaled with two microelectrodes (2–3mΩ) which were
ﬁlled with 2mM KCl. All recordings were performed at room
temperature at a holding potential of –60mV using a Warner
OC-725C two-electrode voltage clamp (Warner Instruments,
Hamden, CT). Data were digitized, recorded and measured
using a Digidata 1322A data acquisition system (Axon Instru-
ments, Union City, CA). Results of concentration response
experiments were graphed using GraphPad Prism 4.00 (Graph-
Pad Software, San Diego, CA).
Maximum GABA-evoked currents (1 mM GABA) were mea-
sured in each oocyte and were in the 4.5–7 μA range for all
receptor subtypes investigated, indicating an adequate
expression of the different receptor subtypes. From these
data, GABA EC3 values were calculated and the oocytes were
then stimulated by the respective GABA concentration, con-
ﬁrming the calculated value. The GABA EC3 current was then
modulated by 1 mM diazepam, which should nearly maxi-
mally modulate the receptors. Further measurements with
the oocyte were only performed if the extent of modulation
by diazepam was in a range corresponding to that shown in
Fig. 1b for the respective receptor subtype.
4.4. Estimation of free plasma and brain concentrations
4.4.1. Quantiﬁcation in rat plasma and brain tissue
Eighteen Wistar male rats (180–220 g, Military Farm, Belgrade,
Serbia) were divided into six treatment groups (3 animals per
group) that intraperitoneally (i.p.) received 0.5 mg/kg SH-I-048A
20min before decapitation, 2 or 10mg/kg SH-I-048 A 20 or
60min before decapitation, or solvent. Blood samples were
collected by cardiac puncture into heparinized tubes then
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brains were rapidly removed, measured and homogenized at
16,000 rpm for 2min by a rotor–stator blender (T 25 digital
Ultra-Turrax, IKA, Germany) in 2mL of methanol. The ﬁnal
volume was adjusted to 5mL with methanol and after centri-
fugation (6000g for 20min) supernatants were collected.
Concentrations of SH-I-048 A in plasma and brain tissue were
determined by ultra performance liquid chromatography-
tandem mass spectrometry (UPLC/MS/MS). The sample pre-
treatment procedure was carried out using solid-phase extrac-
tion (SPE) on Oasiss HLB cartridges (Waters, Milford, MA, USA).
The procedure was adapted from the method reported by
Mercolini et al. (2009). Brieﬂy, cartridges preconditioned with
methanol and water were loaded with samples (plasma or
supernatant of brain tissue homogenate) and the internal
standard solution. Endogenous impurities were removed by
washing the cartridges with water andmethanol. Finally, analyte
elution was carried out with 1mL of methanol for 1min.
4.4.2. Plasma protein and brain tissue binding studies
A 48-well rapid equilibrium dialysis (RED) device (Thermo
Scientiﬁc) was used to determine SH-I-048 A free fraction in
fresh rat plasma and brain tissue. Brain samples were diluted
with 4 volumes of PBS and homogenized. The sample chambers
of the RED device insert were loaded with 190 mL of plasma or
brain tissue homogenate and 10 mL of SH-I-048A working
solution in DMSO (100 mM) in order to obtain a ﬁnal SH-I-048A
concentration of 5 mM. A 350 mL of PBS were transferred into the
buffer chamber of the insert. After incubation at 37 1C on an
orbital shaker for 4 h, 50 mL of buffer, plasma and brain homo-
genate aliquots were transferred to microcentrifuge tubes con-
taining equal volume of DMSO. A 50 mL volume of control buffer
was added to the plasma and brain homogenate samples and
50 mL of either control brain homogenate or control plasma was
added to the buffer sample to yield an identical matrix between
buffer and nonbuffer samples. Sample extraction was per-
formed by the addition of 300 mL of chilled acetonitrile contain-
ing midazolam as an internal standard. After vortexing and
centrifuging, 120 mL of supernatant were transferred to vials for
UPLC/MS/MS analysis. The same protocol was applied for the
matrix preparation for standard curves except that 50 mL of
drug-free dialyzed plasma, brain homogenate and buffer were
added to microcentrifuge tubes containing 50 mL of SH-I-048A
standard solutions in DMSO over the concentration range from
50 mM to 0.5 mM.
The unbound fraction in plasma was determined as the
ratio of concentrations determined in buffer to that deter-
mined in plasma. The unbound fraction in undiluted brain
was calculated by using the following equation: undiluted
fu¼ {1/Dn[(1/ fu(apparent)  1)þ1/D]} (Kalvass and Maurer, 2002),
where D and fu(apparent) represent dilution factor and free
fraction determined as the ratio of concentrations in buffer
vs. diluted brain tissue, respectively.
4.5. Behavioral experiments
In vivo studies were carried out on male Wistar rats (Military
Farm, Belgrade, Serbia), weighing 180–220 g at the beginning
of the experiments. All procedures in the study conformed to
EEC Directive 86/609 and were approved by the EthicalCommittee on Animal Experimentation of the Faculty of
Pharmacy in Belgrade, or, for the peripheral nerve injury
model, Medical Faculty in Belgrade. The rats were group-
housed four per cage (in the peripheral nerve injury model
two per cage) in transparent plastic cages with tap water and
food pellets available ad libitum and kept under a 12 h light/
dark cycle (light on at 6:00 h). The temperature of the animal
room was 2271 1C, the relative humidity is 40–70% and the
illumination is 120 lx. With the exception of the second
treatment in the peripheral nerve injury model, all handling
and testing took place during the light period of the cycle.
Ligands were dissolved/suspended with the aid of sonication
in solvent containing 85% distilled water, 14% propylenegly-
col, and 1% Tween 80, and were administered i.p. in a volume
of 1 mL/kg.
Separate groups of naïve animals were used for seven
behavioral paradigms. For all behavioral studies, with the
exception of the peripheral nerve injury model, the positive
control experiments (2 mg/kg diazepam, with the accompany-
ing solvent control) have been performed separately during the
period when experiments with SH-I-048 A were carried out. The
behavior in spontaneous locomotor activity (SLA), open ﬁeld
(OF), Morris water maze (MWM) and elevated plus maze (EPM)
was recorded by a ceiling-mounted camera and analyzed by the
ANY-maze Video Tracking System software (Stoelting Co.,
Wood Dale, IL, USA). The rats' behavior in rotarod (RR) and grip
strength (GS) tests, as well as in peripheral nerve injury (PNI)
model, was recorded automatically by the apparatus. Where
applicable, olfactory traces left in the apparatus were removed
after each testing using diluted ethanol.
4.5.1. Spontaneous locomotor activity test
The rats' spontaneous locomotor activity was monitored in a
clear Plexiglas open chamber (402535 cm) without any
prior habituation to this apparatus. Twenty minutes after
receiving the appropriate treatment, a single rat was placed
in the chamber, under dimmed red light (20 lx), and activity
was recorded for a total of 30 min. The total distance traveled
(m) was the activity parameter evaluated in four treatment
groups (solvent and SH-I-048 A, dosed at 2, 5 and 10 mg/kg).
Besides the total distance traveled, behavior was analyzed by
breaking the locomotor activity data into 5-min bins.
4.5.2. Elevated plus maze test
The apparatus was constructed of sheet metal, with a black
rubber ﬂoor. It consisted of a maze elevated to a height of
50 cm with two open (5010 cm) and two enclosed arms
(501040 cm), connected by a junction area measuring
1010 cm. A ledge of sheet metal (0.3 cm high) surrounded
the open arms. The red illumination on the surface of the
closed arms was 10 lx. At the beginning of the experiment,
single rats were placed in the center of the maze, facing one of
the enclosed arms, and their behavior was recorded for 5 min.
An entry into an open or closed arm was scored when 80% of
the animal crossed the virtual line separating the central
square of the maze from the arm, whereas an exit occurred
when more than 80% of the animal left the respective arm. In
this experiment we used four treatment groups: solvent and
SH-I-048A dosed at 2, 5 and 10mg/kg. In a preliminary study,
we tested also the 0.5 mg/kg dose of SH-I-048A.
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The OF arena consisted of a square wooden box
(10010050 cm3), with a black rubber ﬂoor. Twenty min-
utes after receiving the appropriate treatment, and without
any prior habituation, a single animal was placed in the
center of the box. The central 16% of the ﬂoor surface
(4040 cm2) was virtually set as a central zone. Animal
activity under dimmed red light (20 lx) was recorded for
15 min. The total distance traveled (m) was evaluated as an
activity parameter, while the percent of time spent in the
central zone, as an anxiety-related parameter, was estimated
in the ﬁrst 5-min period. In this experiment we used ﬁve
treatment groups: solvent and SH-I-048A dosed at 0.2, 0.5, 2
and 10 mg/kg.
4.5.4. Grip strength test
Myorelaxant properties of SH-I-048A, dosed at 0.5, 2, 5 and
10 mg/kg, were examined in this study. Twenty minutes after
administration of the appropriate treatment rats were
allowed to grasp with their front paws a metal trapezoid
wire grid attached to a grip-strength meter (Ugo Basile, Italy),
while being lifted by the tail with increasing ﬁrmness until
they loosened their grip. Every testing was performed by the
same experimenter. The apparatus measured the pull force
(expressed in grams) necessary to overcome the animal's
forelimbs grip-strength. Each animal was given three con-
secutive trials and the median value was taken in the
statistics. Dependent variable chosen was calculated by
dividing the pull force with the rat’s body weight.
4.5.5. Rotarod test
Motor performance was assessed using an automated rotarod
(Ugo Basile, Italy). Before testing, rats were trained for three
days until they could remain on a revolving rod for 120 s with
acceleration from 15 rpm to 25 rpm. During the training days,
all animals were given three training sessions of 2 min each,
with a 30 min inter-session interval. On the fourth day,
selection was made and rats that ﬁt the given criteria were
included in the experiment. Four groups received one of the
following treatments: SH-I-048A (10 and 25 mg/kg) alone or in
combination with β-CCt (30 mg/kg). Latency to fall from the
rotarod was recorded automatically for each animal after 30,
60 and 90 min.
4.5.6. Morris water maze test
The water maze consisted of a black cylindrical pool (dia-
meter, 200 cm; height, 60 cm) ﬁlled to a height of 30 cm with
23 1C (71 1C) water. The escape platform made of black
plastic (1510 cm) was submerged 2 cm below the water
surface. An indirect illumination in the experimental room
was provided by white neon tubes. The rats received the
appropriate treatment 20 min before a swimming block, each
day for 5 consecutive days of spatial acquisition. Each block
consisted of 4 trials, lasting a maximum time of 120 s, the
intertrial interval being 60 s. For each trial the rat was placed
in the water facing the pool at one of four pseudorandomly
determined starting positions. Since the platform was hidden
in the middle of the NE quadrant during spatial learning, the
four distal start locations were S, W, NW and SE. Once the rat
found and mounted the escape platform, it was permitted toremain on it for 15 s. The rat was guided to the platform by
the experimenter if it did not locate the escape within 120 s.
For each training day and parameter measured in the water
maze the mean value was calculated for each rat (total data/
total number of trials). To assess the reference memory at the
end of the learning period, a probe trial was conducted 24 h
after the last acquisition day. The probe trial, starting from
the novel, most distant SW location, with the platform
omitted, lasted 60 s and was performed without any pre-
treatment. The tracking software virtually divided the pool
into four quadrants, three concentric annuli and a target
region consisting of the intersection of the platform quadrant
and the platform (middle) annulus, as graphically repre-
sented in Savić et al. (2009).
Dependent variables chosen for tracking during the acqui-
sition trials were the latency to reach the platform (time from
the start to the goal) and the path efﬁciency (the ratio of the
shortest possible path length to actual path length). In
addition, the latency to the ﬁrst entry to the target zone
and the path efﬁciency to the ﬁrst entry to the target zone
were assessed during the probe trial. In the water maze study
we used four treatment groups: solvent and SH-I-048A dosed
at 0.5, 2 and 10 mg/kg.
4.5.7. Peripheral nerve injury model
The animals were habituated in individual Plexiglas cham-
bers for 30 min before testing. Electronic von Frey apparatus
(Model 2390, IITC Life Science – USA) was used to determine
paw withdrawal threshold expressed in grams. An increasing
pressure of maximum 80 g was intermittently applied to
the right and left rat hind paw for three times each, until
the animal showed a typical paw withdrawal reaction. Base-
line withdrawal scores were obtained before injury (0 h).
To induce PNI model, we performed a crush injury to the
right sciatic nerve. Rats were anesthetized with ketamine
solution (10% Ketamidor, Richter Pharma Ag, Wels, Austria).
After the right external thigh and buttock area had been
shaved, the skin was properly prepared with antiseptic
solution and alcohol, and small incision was made. The m.
vastus lateralis and m. biceps femoralis were bluntly sepa-
rated at the mid-thigh level. The nerve was kept in situ. At
approximately 7 mm from the point of its emergence, the
common sciatic nerve was mobilized and traumatized by a
single 30-s crush with a serrated hemostat (Bridge et al.,
1994). After surgery animals were separated in four groups.
Treatments were administered three times: immediately
after surgery, after 12 h and ﬁnally after 23 h. The treatment
groups were solvent three times, one dose of SH-I-048A
(10 mg/kg); solvent two times, two doses of SH-I-048A
(10 mg/kg); and solvent once and three doses of SH-I-048A
(10 mg/kg). After 24 and 48 h, mechanical hyperalgesia was
determined in both hind paws. The graph shows the ratios
between the right hind paw and left hind paw responses,
obtained by dividing the two values and then multiplying the
result by 100 for a better graph representation.
4.6. Statistical analysis
For electrophysiological data, as well as for behavioral data
presented in Table 3, Student's t-test was used. Other
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and normality prior to analysis by a one-way ANOVA (SLA, OF,
EPM and GS tests), or a two-way ANOVA (RR test). In order to
fully investigate the rats’ behavior in the EPM, an analysis of
covariance (ANCOVA) was performed for the percentage of time
spent on open arms, as an anxiety-related parameter, using the
number of enclosed arm entries as covariate. Data from MWM
and PNI model were assessed with a two-way ANOVA with
repeated measures (treatment as between-subject factor and
day or time, respectively, as within-subject factor). In the case
of signiﬁcant interaction, separate one-way ANOVAs were
conducted to assess the inﬂuence of one factor within indivi-
dual levels of other factor. For post hoc analysis, Dunnett’s or
Tukey’s test were used. Statistical analyses were performed
with ANY-maze Video Tracking System software (Stoelting Co.,
Wood Dale, IL, USA) and Sigma Plot 11 (Systat Software Inc.,
Richmond, CA, USA). Differences were considered to be statis-
tically signiﬁcant when p was less than 0.05, while 0.14p40.05
was considered as a trend toward signiﬁcance.Acknowledgement
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